Australia's most trusted source of pharma news
Sunday, 05 July 2015
Lost Your Access?
Former Sigma bosses may go to jail
The former CEO and CFO of wholesaler Sigma are facing potential jail sentences after pleading guilty to falsifying the companys accounts in 2009 and 2010.
AZ and Adelaide Uni seal R&D pact
AstraZeneca will hand over 50 compounds to Adelaide Uni in return for first rights to new discoveries.
WHO updates biologicals naming
The WHO has updated its naming conventions for Biological Qualifiers under the INN system, following requests from some drug regulatory authorities.
New Sunshine payments top US$6bn
Australian pharma's payments to doctors are little compared to the US, with industry there reporting a total of US$6.49 billion in 2014.
Remicade has 'large signal' for TB
Tuberculosis was the main adverse event reported for RA treatments, with Janssen's
having the highest reporting odds ratio for it.
Pharma sends 500 Aussie HCPs abroad
Pharma companies sent more than 500 Australian HCPs on overseas study trips between October 2014 and March 2015, spending an average of $8,250 each.
Aussie MDs in the dark on costs
Under questioning from senators at the corporate tax avoidance inquiry, heads of nine pharma companies have shown they know little about their cost of sales.
Drug pricing an 'endemic' tax risk
The Tax Office has characterised pharma as an "industry with endemic risk ... its one that just doesn't go away" when it comes to transfer pricing.
HCP hospitality costs up 84% in 2014
The average cost of hospitality per HCP consultant went up around 84 per cent in 2014, even as the total consulting fees went down by around 12 per cent.
Ley hits back at MSD on Keytruda
The government has hit back at MSD, calling its claims about a potential May 1 listing for its melanoma treatment
Novartis acquires Aussie pain biotech
Novartis has bought Australian biotechnology company Spinifex for US$200m in a deal that will deliver the major a promising novel chronic pain treatment.
Keytruda's fast listing not fast enough
MSD has won one of the fastest listings for cancer drugs with its melanoma treatment
but a September 1 listing is not soon enough.
Ley blames pharma for slow access
Health Minister Sussan Ley has used the release of the Sansom report on the TGA to continue her attacks on the pharmaceutical industry.
No guarantee against more cuts
The first round of cuts to F1 drugs will start in April 2016 and says MA, the government has refused to guarantee they'll be the last.
We pay our Aussie taxes says Pfizer
Pfizer's effective tax rate on underlying profit is 'consistently above 30 per cent', even when loss before tax was recorded, the company has said.
Generics access under trade threat
The GMiA shares international generics industry concern that Trans-Pacific Partnership could delay access to generic medicines and biosimilars.
PBS sets out new pharmacy fees
The PBS has released new documents with details of the administration, handling and infrastructure fee for pharmacists.
TGA faster and cheaper for some
In a boost for the generics industry, the TGA has brought in new, less expensive measures for extending indications in generics and adding trade names.
Pharma's HCP education spend falls
Pharma companies spent $33.4m on educational events between October 2014 and March 2015 - $4m less than for the same period last year.
Court finds Abilify patent lacks novelty
Otsuka and BMS have not ruled out an appeal against a Federal Court finding that a patent over schizophrenia treatment
Bayer tops HCO spending
Bayer last year spent more than $1.66m on health consumer organisations, in a year that saw spending total more than $10m across different causes.
Pharma supply chain challenges abound
Saul Resnick, Managing Director, DHL Supply Chain Australia, looks at how pharma can be smarter about their use of supply chains.
Anticoagulant and blood thinner approved
Approval for anticoagulant, blood thinner while new class of cancer medicine, enzyme replacement therapies and a swag of others bag recommendations.
Do appearances matter?
While tattoos and piercings are becoming more mainstream in younger generations, the pharmaceutical industry continues to be very conservative. So, what can you expect for yourself or your staff in regard to appearance?
Image problems continue to beset pharma
A spate of mainstream media coverage from tax to medicine prices to trade agreements continues to portray Aussie pharma in a negative light - does the industry have only itself to blame?
Big changes proposed at TGA
A wide range of changes have been mooted for the regulator which could speed up approval of medicines and see more information shared post- market, with other regulators and across reimbursement applications.
Events & Conferences
© 2003 - 2015 Lush Media
Pharma in Focus
Jolly Good Design
christian louboutin Sandals
hermes replica belt
celine tote sale
yves saint laurent discount
prada replica bags
hermes birkin replica
hermes handbags birkin
christian louboutin pumps outlet
hermes kelly replica
chloe handbags replica
hermes replica handbags
celine trapeze sale
hermes kelly outlet
yves saint laurent shoulder bags replica
christian louboutin Sandals replica
chloe handbags online